drugset / Trial / NCT05339256
Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual
Phase 2
Not yet recruiting
50 enrolled
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will compare in-person induction and maintenance dosing of sublingual buprenorphine to induction and maintenance dosing of sublingual buprenorphine through comprehensive telehealth sessions and telehealth medication for opioid use disorder (MOUD).
Timeline
- Start
- 2026-06-01
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buprenorphine | Other / unclassified | 24 mg | Subcutaneous |